CURRENT DRUG DELIVERY, vol.16, no.6, pp.511-529, 2019 (SCI-Expanded)
Article / Article
CURRENT DRUG DELIVERY
Science Citation Index Expanded (SCI-EXPANDED), Scopus
Triple Negative Breast Cancer (TNBC), PARP inhibitors, Talazoparib (BMN 673), Solid Lipid Nanoparticles (SLNs), Apoptosis, cytotoxic effects, DRUG-DELIVERY-SYSTEMS, INHIBITOR BMN 673, PARP INHIBITOR, DNA-REPAIR, MULTIDRUG-RESISTANCE, SYNTHETIC LETHALITY, HIGHLY POTENT, CANCER, CYTOTOXICITY, PACLITAXEL
Eskisehir Osmangazi University Affiliated:
Objective: In the present work, we report for the first time the therapeutic potential of talazoparib (BMN 673)-SLNs for the treatment of BRCA1 deficient Triple Negative Breast Cancer (TNBC). BMN 673-SLNs were produced by hot-homogenization technique and then characterized.